Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients

Andrea Panunzio; Stefano Tappero; Cristina Cano Garcia; Mattia Piccinelli; Francesco Barletta; Reha-Baris Incesu; Zhe Tian; Alessandro Tafuri; Derya Tilki; Alberto Briganti; Ottavio DE Cobelli; Felix K H Chun; Carlo Terrone; Fred Saad; Shahrokh F Shariat; Isabelle Bourdeau; Maria Angela Cerruto; Alessandro Antonelli; Pierre I Karakiewicz

doi:10.21873/anticanres.16065

Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients

Standard

Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients. / Panunzio, Andrea; Tappero, Stefano; Garcia, Cristina Cano; Piccinelli, Mattia; Barletta, Francesco; Incesu, Reha-Baris; Tian, Zhe; Tafuri, Alessandro; Tilki, Derya; Briganti, Alberto; DE Cobelli, Ottavio; Chun, Felix K H; Terrone, Carlo; Saad, Fred; Shariat, Shahrokh F; Bourdeau, Isabelle; Cerruto, Maria Angela; Antonelli, Alessandro; Karakiewicz, Pierre I.

in: ANTICANCER RES, Jahrgang 42, Nr. 11, 11.2022, S. 5579-5585.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Panunzio, A, Tappero, S, Garcia, CC, Piccinelli, M, Barletta, F, Incesu, R-B, Tian, Z, Tafuri, A, Tilki, D, Briganti, A, DE Cobelli, O, Chun, FKH, Terrone, C, Saad, F, Shariat, SF, Bourdeau, I, Cerruto, MA, Antonelli, A & Karakiewicz, PI 2022, 'Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients', ANTICANCER RES, Jg. 42, Nr. 11, S. 5579-5585. https://doi.org/10.21873/anticanres.16065

APA

Panunzio, A., Tappero, S., Garcia, C. C., Piccinelli, M., Barletta, F., Incesu, R-B., Tian, Z., Tafuri, A., Tilki, D., Briganti, A., DE Cobelli, O., Chun, F. K. H., Terrone, C., Saad, F., Shariat, S. F., Bourdeau, I., Cerruto, M. A., Antonelli, A., & Karakiewicz, P. I. (2022). Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients. ANTICANCER RES, 42(11), 5579-5585. https://doi.org/10.21873/anticanres.16065

Vancouver

Panunzio A, Tappero S, Garcia CC, Piccinelli M, Barletta F, Incesu R-B et al. Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients. ANTICANCER RES. 2022 Nov;42(11):5579-5585. https://doi.org/10.21873/anticanres.16065

Bibtex

@article{bdc8ca286248420f832b385b8608b0b8,

title = "Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients",

abstract = "BACKGROUND/AIM: In primaries other than adrenocortical carcinoma (ACC), Hispanic race/ethnicity may predispose to higher stage at initial diagnosis and may result in worse survival. We tested the association between Hispanic race/ethnicity and cancer specific mortality (CSM) in ACC patients in addition to testing for differences in other-cause mortality (OCM) rates between Hispanics and Caucasians.PATIENTS AND METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 1,060 ACC patients: 167 (15.8%) Hispanics vs. 893 (84.2%) Caucasians. Propensity score matching (age, sex, grade, T, N and M stages, treatment types), cumulative incidence plots Poisson-smoothing and competing risk regression (CRR) were used.RESULTS: Compared to Caucasians, Hispanics were younger (51 vs. 57 years, p<0.001) and presented higher rates of T3-4 primary tumor stage (52.7% vs. 42.8%, p=0.007). No other statistically significant differences were observed for grade, lymph node invasion, distant metastases, European Network for the Study of Adrenal Tumors (ENSAT) stage and treatment type (p>0.05 in all cases). After matching (1:3), 167 Hispanics and 501 Caucasians remained and were included in CRR analyses. In Hispanics, five-year CSM rates were 38.0% and 78.8% in respectively ENSAT stages I-II and III-IV vs. 34.1% and 74.4% in Caucasians. Overall, five-year OCM rates were 10.7% vs. 9.0% in Hispanics and Caucasians, respectively. In multivariable CRR models, Hispanic race/ethnicity was not an independent predictor for higher CSM (hazard ratio=1.18, p=0.2).CONCLUSION: In ACC, relative to Caucasians, Hispanic race/ethnicity is associated with lower age at initial diagnosis, but not with higher tumor stage or survival disadvantage.",

keywords = "Humans, White People, Adrenocortical Carcinoma, Hispanic or Latino, Ethnicity, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms",

author = "Andrea Panunzio and Stefano Tappero and Garcia, {Cristina Cano} and Mattia Piccinelli and Francesco Barletta and Reha-Baris Incesu and Zhe Tian and Alessandro Tafuri and Derya Tilki and Alberto Briganti and {DE Cobelli}, Ottavio and Chun, {Felix K H} and Carlo Terrone and Fred Saad and Shariat, {Shahrokh F} and Isabelle Bourdeau and Cerruto, {Maria Angela} and Alessandro Antonelli and Karakiewicz, {Pierre I}",

year = "2022",

month = nov,

doi = "10.21873/anticanres.16065",

language = "English",

volume = "42",

pages = "5579--5585",

journal = "ANTICANCER RES",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "11",

}

RIS

TY - JOUR

T1 - Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients

AU - Panunzio, Andrea

AU - Tappero, Stefano

AU - Garcia, Cristina Cano

AU - Piccinelli, Mattia

AU - Barletta, Francesco

AU - Incesu, Reha-Baris

AU - Tian, Zhe

AU - Tafuri, Alessandro

AU - Tilki, Derya

AU - Briganti, Alberto

AU - DE Cobelli, Ottavio

AU - Chun, Felix K H

AU - Terrone, Carlo

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Bourdeau, Isabelle

AU - Cerruto, Maria Angela

AU - Antonelli, Alessandro

AU - Karakiewicz, Pierre I

PY - 2022/11

Y1 - 2022/11

N2 - BACKGROUND/AIM: In primaries other than adrenocortical carcinoma (ACC), Hispanic race/ethnicity may predispose to higher stage at initial diagnosis and may result in worse survival. We tested the association between Hispanic race/ethnicity and cancer specific mortality (CSM) in ACC patients in addition to testing for differences in other-cause mortality (OCM) rates between Hispanics and Caucasians.PATIENTS AND METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 1,060 ACC patients: 167 (15.8%) Hispanics vs. 893 (84.2%) Caucasians. Propensity score matching (age, sex, grade, T, N and M stages, treatment types), cumulative incidence plots Poisson-smoothing and competing risk regression (CRR) were used.RESULTS: Compared to Caucasians, Hispanics were younger (51 vs. 57 years, p<0.001) and presented higher rates of T3-4 primary tumor stage (52.7% vs. 42.8%, p=0.007). No other statistically significant differences were observed for grade, lymph node invasion, distant metastases, European Network for the Study of Adrenal Tumors (ENSAT) stage and treatment type (p>0.05 in all cases). After matching (1:3), 167 Hispanics and 501 Caucasians remained and were included in CRR analyses. In Hispanics, five-year CSM rates were 38.0% and 78.8% in respectively ENSAT stages I-II and III-IV vs. 34.1% and 74.4% in Caucasians. Overall, five-year OCM rates were 10.7% vs. 9.0% in Hispanics and Caucasians, respectively. In multivariable CRR models, Hispanic race/ethnicity was not an independent predictor for higher CSM (hazard ratio=1.18, p=0.2).CONCLUSION: In ACC, relative to Caucasians, Hispanic race/ethnicity is associated with lower age at initial diagnosis, but not with higher tumor stage or survival disadvantage.

AB - BACKGROUND/AIM: In primaries other than adrenocortical carcinoma (ACC), Hispanic race/ethnicity may predispose to higher stage at initial diagnosis and may result in worse survival. We tested the association between Hispanic race/ethnicity and cancer specific mortality (CSM) in ACC patients in addition to testing for differences in other-cause mortality (OCM) rates between Hispanics and Caucasians.PATIENTS AND METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 1,060 ACC patients: 167 (15.8%) Hispanics vs. 893 (84.2%) Caucasians. Propensity score matching (age, sex, grade, T, N and M stages, treatment types), cumulative incidence plots Poisson-smoothing and competing risk regression (CRR) were used.RESULTS: Compared to Caucasians, Hispanics were younger (51 vs. 57 years, p<0.001) and presented higher rates of T3-4 primary tumor stage (52.7% vs. 42.8%, p=0.007). No other statistically significant differences were observed for grade, lymph node invasion, distant metastases, European Network for the Study of Adrenal Tumors (ENSAT) stage and treatment type (p>0.05 in all cases). After matching (1:3), 167 Hispanics and 501 Caucasians remained and were included in CRR analyses. In Hispanics, five-year CSM rates were 38.0% and 78.8% in respectively ENSAT stages I-II and III-IV vs. 34.1% and 74.4% in Caucasians. Overall, five-year OCM rates were 10.7% vs. 9.0% in Hispanics and Caucasians, respectively. In multivariable CRR models, Hispanic race/ethnicity was not an independent predictor for higher CSM (hazard ratio=1.18, p=0.2).CONCLUSION: In ACC, relative to Caucasians, Hispanic race/ethnicity is associated with lower age at initial diagnosis, but not with higher tumor stage or survival disadvantage.

KW - Humans

KW - White People

KW - Adrenocortical Carcinoma

KW - Hispanic or Latino

KW - Ethnicity

KW - Adrenal Gland Neoplasms

KW - Adrenal Cortex Neoplasms

U2 - 10.21873/anticanres.16065

DO - 10.21873/anticanres.16065

M3 - SCORING: Journal article

C2 - 36288855

VL - 42

SP - 5579

EP - 5585

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 11

ER -